Director Share Purchases

RNS Number : 2412M
Evgen Pharma PLC
19 January 2016
 

For immediate release                                                                                                                 19 January 2016

 

 

Evgen Pharma plc

 

("Evgen" or the "Company")

 

Director Share Purchases

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 18 January 2016, certain Directors purchased an aggregate of 136,000 ordinary shares of 0.25 pence each at a price of 22.5 pence per share.  The Directors participating in the purchase and their interests in the share capital of the Company following the purchase are as follows:

Director

Number of Ordinary Shares pursuant to Directors' dealing

Holding following Directors' dealing

Percentage of Ordinary Shares following Directors' dealing

 

 

 

 

Barry Clare

40,000

940,108

1.3%

Stephen Franklin

56,000

1,375,200

1.9%

John Bradshaw

40,000

40,000

0.1%

 

Enquiries:

Evgen Pharma plc

+44 (0) 20 7466 5000

Dr Stephen Franklin, CEO

 

www.evgen.com

 

 

 

Northland Capital Partners Limited

+44 (0) 20 7382 1100

Matthew Johnson, Gerry Beaney,
Margarita Mitropoulou (Corporate Finance)

 

John Howes (Corporate Broking)

 

 

 

Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Stephanie Watson

 

 

 

 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  For further information please visit www.evgen.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBPMRTMBABBFF
UK 100

Latest directors dealings